Ma Jun, Yang Xinjian, Yin Hao, Wang Yang, Chen Hongbin, Liu Chuangxi, Han Guoqiang, Gao Fangyou
Department of Interventional Neuroradiology, Beijing Neurosurgical Institute and Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China ; Department of Neurosurgery, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, P.R. China.
Department of Interventional Neuroradiology, Beijing Neurosurgical Institute and Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China.
Exp Ther Med. 2015 Jul;10(1):369-373. doi: 10.3892/etm.2015.2475. Epub 2015 May 7.
Aneurysmal subarachnoid hemorrhage (aSAH) is a recently identified risk factor for chronic hypothyroidism. Patients with hypothyroidism often exhibit cognitive dysfunction. The aim of the present study was to determine the effects of thyroid hormone replacement therapy on cognition in aSAH survivors with hypothyroidism. A study population of 135 patients was recruited and subjected to the Montreal Cognitive Assessment (MoCA) and Beck Depression Inventory. Among the study population, 52 patients exhibited cognitive dysfunction. Thyroid hormone levels were measured in these patients using an electrochemiluminescence immunoassay in order to elucidate possible deficits in the thyrotrophic hormonal axes, and hypothyroidism was confirmed in 31 patients. Among these 31 patients, 22 patients consented to be randomized into groups and were administered levothyroxine replacement or a placebo treatment for 3 months. The MoCA and Wechsler Adult Intelligence Scale-Chinese version (WAIS-RC) testing were performed prior to and following the replacement therapy or placebo treatments. All subjects completed the study with no negative side effects. After 8-12 weeks of oral levothyroxine administration, it was observed that the serum concentration of thyroid-stimulating hormone was restored to normal levels. Furthermore, neuropsychological test results improved following the replacement therapy. A significant improvement was observed in the MoCA scores of the replacement group following therapy, with the exception of the score for abstraction. Additionally, significant improvements in the WAIS-RC were observed in the replacement group, with the exceptions of the information comprehension and letter-number sequencing scores. Thus, the present study has demonstrated the partial normalization of cognitive impairments in patients with hypothyroidism following aSAH as a result of appropriate levothyroxine replacement therapy.
动脉瘤性蛛网膜下腔出血(aSAH)是最近确定的慢性甲状腺功能减退症的一个风险因素。甲状腺功能减退症患者常表现出认知功能障碍。本研究的目的是确定甲状腺激素替代疗法对aSAH合并甲状腺功能减退症幸存者认知功能的影响。招募了135名患者作为研究对象,并对其进行蒙特利尔认知评估(MoCA)和贝克抑郁量表测试。在研究对象中,52名患者表现出认知功能障碍。使用电化学发光免疫分析法测量这些患者的甲状腺激素水平,以阐明甲状腺激素轴可能存在的缺陷,31名患者被确诊为甲状腺功能减退症。在这31名患者中,22名患者同意被随机分组,并接受左甲状腺素替代治疗或安慰剂治疗3个月。在替代治疗或安慰剂治疗前后进行MoCA和韦氏成人智力量表中文版(WAIS-RC)测试。所有受试者均完成了研究,且无负面副作用。口服左甲状腺素8 - 12周后,观察到促甲状腺激素的血清浓度恢复到正常水平。此外,替代治疗后神经心理学测试结果有所改善。治疗后,替代组的MoCA评分除抽象能力得分外均有显著提高。此外,替代组的WAIS-RC评分除信息理解和字母数字排序得分外也有显著提高。因此,本研究表明,aSAH合并甲状腺功能减退症患者通过适当的左甲状腺素替代治疗后,认知障碍部分恢复正常。